Zacks Investment Research downgraded shares of Radius Health (NASDAQ:RDUS) from a hold rating to a sell rating in a report released on Thursday morning.
According to Zacks, “Radius got a boost with the approval of lead drug Tymlos. Sales of Tymlos continue to gain traction. Total prescriptions accounted for 22% of total U.S. anabolic osteoporosis market (based on Patient Months on Therapy, TRx PMOT) in the quarter. Tymlos is expected to be covered for approximately 274 million insured lives, representing approximately 95% of U.S. commercial and 64% of Medicare insured lives effective Jan 1, 2019. However, Radius suffered a setback when the CHMP communicated a negative trend vote for the MAA following a re-examination procedure of lead drug Tymlos. Thereafter, the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the last six months.”
RDUS has been the topic of a number of other reports. BidaskClub downgraded shares of Radius Health from a sell rating to a strong sell rating in a report on Tuesday, November 13th. ValuEngine downgraded shares of Radius Health from a hold rating to a sell rating in a report on Wednesday, January 2nd. JPMorgan Chase & Co. reduced their price target on shares of Radius Health from $59.00 to $52.00 and set an overweight rating on the stock in a report on Friday, November 2nd. Finally, Cowen reiterated a hold rating on shares of Radius Health in a report on Tuesday, November 6th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $44.50.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.17. The company had revenue of $27.70 million for the quarter, compared to the consensus estimate of $26.00 million. Radius Health had a negative net margin of 346.67% and a negative return on equity of 140.79%. Radius Health’s revenue for the quarter was up 105.2% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.31) EPS. On average, equities analysts forecast that Radius Health will post -5.17 EPS for the current fiscal year.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 60,000 shares of Radius Health stock in a transaction dated Friday, December 14th. The stock was acquired at an average price of $15.64 per share, for a total transaction of $938,400.00. Following the acquisition, the insider now owns 6,650,276 shares in the company, valued at approximately $104,010,316.64. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Joseph Francis Kelly purchased 3,000 shares of Radius Health stock in a transaction dated Monday, December 17th. The stock was acquired at an average price of $15.71 per share, with a total value of $47,130.00. Following the acquisition, the vice president now owns 3,000 shares in the company, valued at approximately $47,130. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 123,000 shares of company stock valued at $1,854,330. 3.42% of the stock is owned by corporate insiders.
Several large investors have recently bought and sold shares of RDUS. HealthCor Management L.P. raised its holdings in shares of Radius Health by 77.0% in the 3rd quarter. HealthCor Management L.P. now owns 3,584,580 shares of the biopharmaceutical company’s stock valued at $63,806,000 after purchasing an additional 1,559,580 shares in the last quarter. BB Biotech AG raised its stake in shares of Radius Health by 6.3% during the 3rd quarter. BB Biotech AG now owns 6,590,276 shares of the biopharmaceutical company’s stock worth $117,307,000 after acquiring an additional 389,363 shares in the last quarter. Man Group plc raised its stake in shares of Radius Health by 352.6% during the 3rd quarter. Man Group plc now owns 496,037 shares of the biopharmaceutical company’s stock worth $8,830,000 after acquiring an additional 386,437 shares in the last quarter. Teachers Advisors LLC raised its stake in shares of Radius Health by 503.7% during the 3rd quarter. Teachers Advisors LLC now owns 446,277 shares of the biopharmaceutical company’s stock worth $7,944,000 after acquiring an additional 372,355 shares in the last quarter. Finally, Rubric Capital Management LP bought a new position in shares of Radius Health during the 3rd quarter worth approximately $4,935,000.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer.
Featured Article: Compound Interest
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.